Medtronic PLC expects its extravascular implantable cardioverter defibrillator (EV ICD) will prove to be more cost-effective than standard ICDs because its substernal lead creates fewer complications than a traditional transvenous ICD lead.
EV ICD provides defibrillation therapy and anti-tachycardia pacing, post-shock pacing and temporary bradycardia pacing. Because the EV ICD’s lead sits below the sternum rather than in the heart’s veins, the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?